TAE Life Sciences (TLS) and Stella Pharma have partnered to advance Boron Neutron Capture Therapy (BNCT) technology in the US and European markets.
The collaboration focuses on developing and commercialising BNCT using Stella Pharma’s boronophenylalanine (BPA) under the product name, Steboronine.
Both companies aim to expand BNCT’s availability for cancer treatment in these regions.
Stella Pharma’s BPA drug is said to be the world’s first clinically approved boron drug for BNCT, marking a major cancer treatment breakthrough.
Japan was the first to approve BNCT for head and neck cancers using Stella Pharma’s BPA.
Now, Stella Pharma has partnered with TAE Life Sciences to expand BNCT adoption globally.
TAE Life Sciences will be the exclusive commercial partner for Stella Pharma’s BPA in these regions, significantly expanding BNCT’s accessibility beyond Asia.
TAE Life Sciences CEO Rob Hill said: “Our partnership with Stella Pharma combines our shared commitment to advancing BNCT as a viable cancer treatment for patients worldwide.
“We are excited to bring the proven benefits of BPA to US and European healthcare institutions and to support BNCT globally with this powerful therapeutic solution.”
Both companies aim to support BNCT equipment vendors worldwide in implementing BPA-based BNCT treatments.
Through partnerships within the BNCT ecosystem, TLS and Stella Pharma aim to expand BNCT’s clinical applications for treating recurrent head and neck cancers and advance studies for other cancers, including brain, skin, breast, oesophagus, and lung cancers.
Stella Pharma president and COO Koki Uehara said: “Our alliance with TAE Life Sciences marks a significant step in expanding the reach of BPA-based BNCT treatments beyond Asia.
“We look forward to collaborating internationally to develop and commercialise BNCT and aim to deliver this advancing cancer treatments to patients and their families worldwide.”
Both partners plan to advance BNCT for hard-to-treat cancers and explore further collaboration opportunities.
Together, they aim to accelerate innovation, expand treatment options, and improve outcomes for cancer patients worldwide.
In April this year, TAE Life Sciences announced the completion of acceptance testing and regulatory registration inspection of its accelerator-based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption.
